Peramivir 200 mg

Phase 2

BioCryst Pharmaceuticals, Inc. (BCRX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Influenza

SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)

Phase 3

BNTXInfluenza and COVID-19 Combination A

Phase 3

BNTXInvestigational COVID-19 Vaccine

Phase 2

NVSSurface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008

Phase 2

View Full Landscape

Drug Information

Target Indication

Influenza

Clinical Trial

NCT00453999

Last updated: 6/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/13/2018

Alpivab

Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

BCRX

BioCryst Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

BCX7353Phase 3

Hereditary Angioedema (HAE)

PeramivirPhase 3

Influenza

OseltamivirPhase 3

Influenza

BCX7353 capsulesPhase 3

Hereditary Angioedema, HAE

BCX4161Phase 3

Hereditary Angioedema

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts